This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ecolab (ECL) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Ecolab (ECL) gains from core Global Industrial and Global Institutional segments in Q1.
Hill-Rom's (HRC) Earnings and Revenues Top Estimates in Q2
by Zacks Equity Research
The strong Q2 performance of Hill-Rom (HRC) is backed by solid core revenue growth, continued margin expansion and strategic investments.
Zimmer Biomet's (ZBH) Q1 Earnings, Revenues Beat Estimates
by Urmimala Biswas
While sales in Americas remains dull, Zimmer Biomet (ZBH) is witnessing strength in the Asia Pacific and EMEA regions.
Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise
by Zacks Equity Research
Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.
Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.
GNC Holdings (GNC) Reports Q1 Earnings, Revenues Down Y/Y
by Zacks Equity Research
Despite year-over-year decline in earnings and revenues, better performing International segment and key developments favor GNC Holdings (GNC) in Q1.
PerkinElmer (PKI) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
PerkinElmer's (PKI) Q1 earnings gain from top-line growth, solid show by Diagnostics segment and strong margins. However, negative currency movement remains a headwind.
Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.
Cerner (CERN) Earnings and Revenues Meet Estimates in Q1
by Zacks Equity Research
Cerner (CERN) gains from Professional Services unit in first-quarter 2019. A decline in bookings raises concern.
The Zacks Analyst Blog Highlights: United Technologies, Lockheed Martin, NextEra Energy, Stryker and Kimberly-Clark
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Technologies, Lockheed Martin, NextEra Energy, Stryker and Kimberly-Clark
Varian (VAR) Q2 Earnings Lag Estimates, Gross Orders Surge
by Zacks Equity Research
Varian (VAR) gains from solid segmental contributions in Q2, raises revenue guidance.
Align Technology (ALGN) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Align Technology (ALGN) reports promising top-line numbers on double-digit increase in Invisalign case shipments from a year ago.
Top Stock Reports for United Technologies, Lockheed Martin & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including United Technologies (UTX), Lockheed Martin (LMT) and NextEra Energy (NEE).
Stryker (SYK) Q1 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q1 earnings.
What's in Store for Tandem Diabetes' (TNDM) Q1 Earnings?
by Zacks Equity Research
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
BioTelemetry (BEAT) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Products like MCT and Ware Holter are likely to aid BioTelemetry (BEAT) in Q1.
Can Diagnostic Revenues Fuel PerkinElmer's (PKI) Q1 Earnings?
by Zacks Equity Research
Strength in PerkinElmer's (PKI) core Diagnostics business is expected to drive Q1 results amid foreign exchange woes.
Varian Medical (VAR) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Varian Medical (VAR) expects to gain significantly from APAC and EMEA regions in fiscal Q2.
Can Core MedSurg Segment Drive Stryker's (SYK) Q1 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine along with an upbeat 2019 view are likely to support Stryker (SYK) in Q1. But integration risks might be a dampener.
Can Five Elements Drive Quest Diagnostics (DGX) Q1 Earnings?
by Zacks Equity Research
Quest Diagnostics (DGX) seems in sync with its strategy to expedite growth and operational excellence.
What's in Store for Edwards Lifesciences' (EW) Q1 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expects to gain from core Critical Care product group in Q1.
Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg
by Zacks Equity Research
Stryker's (SYK) emergency care department offers a broad range of products and systems.
Stryker (SYK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Solid Consumables Drive Illumina's (ILMN) Q1 Earnings?
by Zacks Equity Research
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Can Medical Devices Strength Drive Abbott (ABT) Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.